PATENT CLAIM ANALYSIS

Application Number: 16028664
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["530", "317000"]

Abstract:
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Claim (Index 1):
A compound represented by: where\n R 11 , R 12  and R 13  are each independently selected from the group consisting of H, halogen, C 1-3 alkoxy, and C 1-3 alkyl (optionally substituted by one, two or three halogens); \n X 1  is OH or NH 2 , \n X 2  is H or OH; \n and pharmaceutically acceptable salts, stereoisomers and hydrates thereof.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 95.0
- Lexical Diversity: 1.42553
- Patent Class: 530.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14764426', '14764411', '14764395', '15625163', '15667014']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.740291836181856
- 35 USC 102 Novelty (BERT): 0.5103083938419634
- Combined Prediction Score: 0.7172934919478668
- Mean Citation Score: 308.09644600000007
- Max Citation Score: 316.3376
- Similarity Product: 262.14291850452423

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test